Ehab Y. Hanna, M.D., FACS, is currently a Professor and Vice Chair of the Department of Head and Neck Surgery with a joint appointment in the Department of Neurosurgery, MD Anderson Cancer Center. He also serves as an Adjunct Professor of Otolaryngology and Head and Neck Surgery at Baylor College of Medicine. He is an internationally recognized head and neck surgeon and expert in the treatment of patients with skull base tumors and head and neck cancer. He is the medical director of the Multidisciplinary Head and Neck Center and co-director of the Skull Base Tumor program. For the last 15 years, Dr. Hanna has consistently been named one of America's Best Doctors and Top Doctors in Cancer. He authored over 350 publications. He co-edited several major textbooks such as Cancer of the Head and Neck and Comprehensive Management of Skull Base Tumors. He is the Editor-in-Chief of the journal of Head
PDF file - 133K, In vitro migration and invasion assays in MDA8788-6 cells. 4 x 104 cells were pl... more PDF file - 133K, In vitro migration and invasion assays in MDA8788-6 cells. 4 x 104 cells were plated in insert wells or Matrigel-coated wells in the presence of 10% FBS. After 48 hours, OSC19 used as a positive control showed massive migration and invasion, whereas MDA8788-6 did not show any of them. The original magnification is x50.
PDF file - 90K, Expression pattern of epithelial-mesenchymal transition markers in early and late... more PDF file - 90K, Expression pattern of epithelial-mesenchymal transition markers in early and late passage SNUC cells. Expression pattern of epithelial markers (pan-keratin and E-cadherin) and mesenchymal markers (α-SMA and vimentin) in both early (at passage number 17 in MDA8788-6 and at passage number 15 in MDA8788-7) and late passage (at passage number 40) in the SNUC cells was analyzed by Western blotting. Both early and late passage of SNUC cells expressed only the epithelial markers and did not expressed mesenchymal markers.
PDF file - 79K, Cytogenetic analysis of the MDA8788-7 cell line. Representative G-banding of MDA8... more PDF file - 79K, Cytogenetic analysis of the MDA8788-7 cell line. Representative G-banding of MDA8788-7 showed the same translocation in MDA8788-6; m1 t (1:17), m2 t (1:22), m3 t (1:15), m4 t (2:12), m5 t (4:15), m6 t (3:6), m7 t (8:19), m8 t (9:10), m9 t (9:16), m10 t (13:13), m11 t (14, 14) and m12 t (18:19).
Purpose: Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive cancer. Despite the... more Purpose: Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive cancer. Despite the use of multimodality treatment, the overall prognosis remains poor. To better understand the biologic features of SNUC and help develop new therapies for the disease, we established SNUC cell lines and characterized their biologic behaviors.Experimental Design: Cell lines were established from a patient with a T4N0M0 SNUC of the right maxillary sinus who was treated with surgical resection at our center. Tumor colonies were harvested and were sequentially replated onto larger plates. Two populations were developed and labeled MDA8788-6 and MDA8788-7. These cell lines were characterized with molecular, biomarker, functional, and histologic analyses.Results: Short tandem repeat genotyping revealed that the cell line is isogenic to the parental tumor, and cytogenetic analysis identified 12 chromosomal translocations. The SNUC cell lines do not form colonies in soft agar but are tumorigenic...
The objective of this study was to report outcomes for 19 consecutive patients with SMARCB1 (INI‐... more The objective of this study was to report outcomes for 19 consecutive patients with SMARCB1 (INI‐1)‐deficient sinonasal carcinoma. Patients were treated from 2014 to 2021 and followed for a median of 22.3 months. The median overall survival (OS) and disease‐free survival (DFS) were 31.8 and 9.9 months, respectively. Patients with nasal cavity or maxillary sinus tumors had 84% better disease‐specific survival (DSS) (hazard ratio [HR], 0.136; 95% confidence interval [CI], 0.028‐0.66; p = .005) and 71% better DFS (HR, 0.29; 95% CI, 0.097‐0.84; p = .041) than patients with other sinonasal sites. Patients who received induction chemotherapy were 76% less likely to die of disease (DSS HR, 0.241; 95% CI, 0.058‐1.00; p = .047). In the largest single‐institution study of SMARCB1‐deficient sinonasal carcinoma to date, OS and DFS approached 3 years and 1 year, respectively, but were better for nasal cavity and maxillary sinus tumors. Patients may benefit from induction chemotherapy.
PDF file - 133K, In vitro migration and invasion assays in MDA8788-6 cells. 4 x 104 cells were pl... more PDF file - 133K, In vitro migration and invasion assays in MDA8788-6 cells. 4 x 104 cells were plated in insert wells or Matrigel-coated wells in the presence of 10% FBS. After 48 hours, OSC19 used as a positive control showed massive migration and invasion, whereas MDA8788-6 did not show any of them. The original magnification is x50.
PDF file - 90K, Expression pattern of epithelial-mesenchymal transition markers in early and late... more PDF file - 90K, Expression pattern of epithelial-mesenchymal transition markers in early and late passage SNUC cells. Expression pattern of epithelial markers (pan-keratin and E-cadherin) and mesenchymal markers (α-SMA and vimentin) in both early (at passage number 17 in MDA8788-6 and at passage number 15 in MDA8788-7) and late passage (at passage number 40) in the SNUC cells was analyzed by Western blotting. Both early and late passage of SNUC cells expressed only the epithelial markers and did not expressed mesenchymal markers.
PDF file - 79K, Cytogenetic analysis of the MDA8788-7 cell line. Representative G-banding of MDA8... more PDF file - 79K, Cytogenetic analysis of the MDA8788-7 cell line. Representative G-banding of MDA8788-7 showed the same translocation in MDA8788-6; m1 t (1:17), m2 t (1:22), m3 t (1:15), m4 t (2:12), m5 t (4:15), m6 t (3:6), m7 t (8:19), m8 t (9:10), m9 t (9:16), m10 t (13:13), m11 t (14, 14) and m12 t (18:19).
Purpose: Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive cancer. Despite the... more Purpose: Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive cancer. Despite the use of multimodality treatment, the overall prognosis remains poor. To better understand the biologic features of SNUC and help develop new therapies for the disease, we established SNUC cell lines and characterized their biologic behaviors.Experimental Design: Cell lines were established from a patient with a T4N0M0 SNUC of the right maxillary sinus who was treated with surgical resection at our center. Tumor colonies were harvested and were sequentially replated onto larger plates. Two populations were developed and labeled MDA8788-6 and MDA8788-7. These cell lines were characterized with molecular, biomarker, functional, and histologic analyses.Results: Short tandem repeat genotyping revealed that the cell line is isogenic to the parental tumor, and cytogenetic analysis identified 12 chromosomal translocations. The SNUC cell lines do not form colonies in soft agar but are tumorigenic...
The objective of this study was to report outcomes for 19 consecutive patients with SMARCB1 (INI‐... more The objective of this study was to report outcomes for 19 consecutive patients with SMARCB1 (INI‐1)‐deficient sinonasal carcinoma. Patients were treated from 2014 to 2021 and followed for a median of 22.3 months. The median overall survival (OS) and disease‐free survival (DFS) were 31.8 and 9.9 months, respectively. Patients with nasal cavity or maxillary sinus tumors had 84% better disease‐specific survival (DSS) (hazard ratio [HR], 0.136; 95% confidence interval [CI], 0.028‐0.66; p = .005) and 71% better DFS (HR, 0.29; 95% CI, 0.097‐0.84; p = .041) than patients with other sinonasal sites. Patients who received induction chemotherapy were 76% less likely to die of disease (DSS HR, 0.241; 95% CI, 0.058‐1.00; p = .047). In the largest single‐institution study of SMARCB1‐deficient sinonasal carcinoma to date, OS and DFS approached 3 years and 1 year, respectively, but were better for nasal cavity and maxillary sinus tumors. Patients may benefit from induction chemotherapy.
Uploads
Papers by Ehab Hanna